The current focus of the biopharmaceutical industry is on process intensification to achieve higher productivity in smaller footprint systems.  When coupled with single-use technology, these intensified processes enable biomanufacturing facilities to be built faster at a lower cost, with more flexibility for reconfiguration and support of regional manufacturing.  Upstream process intensification has focused on high cell density perfusion processes operated over longer durations to increase facility throughput and utilization.  For downstream, a multi-column continuous chromatography process can be coupled to the perfusion culture to capture and purify product.  This process was demonstrated at-scale at Just Biotherapeutics in collaboration with Merck & Co., Inc.  Data will be presented on protein A step performance, visualization tools used to monitor the operation, and bioburden control. <br/>

At-scale demonstration of an integrated continuous multi-column chromatography process

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.